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At the age of 7, I required an urgent opera-
tion for a broken, awfully deformed wrist.
It was the first day of “summer” vaca-
tion in Tahiti where I lived, which made
it even more painful. On the other hand, it
became a revelation as I was offered the
restricted opportunity to enter an oper-
ating room. Despite premedication and
blurred vision, I clearly remember this sur-
reptitious atmosphere of the OR, the place
where magic happens. I wanted to become
a magician; I decided to be a surgeon.
Years have passed and medicine has
advanced. Magnificently, if one considers
the numerous new drugs and devices that
have been developed, as well as the vari-
ous technologies such as those now rou-
tinely used in imaging and surgical facili-
ties. Heart surgery is certainly a good exam-
ple to illustrate this splendid progression,
as many approaches regularly performed
nowadays were simply not imaginable only
a couple of decades ago. Importantly, not
only have the techniques changed, the
results have greatly improved as well.
SO WHAT CANWE DO NOW?
Have we reached our limit? Can we not do
better than what some of us already con-
sider as good enough? And even if we can
perform better, do we want this and, simply,
can we afford it?
These are legitimate questions, which
preoccupy essentially politicians and insur-
ance providers, although it should be us,
cardiac surgeons, who take control of
our future, or at least provide our politi-
cal, administrative, industrial, and regula-
tory partners with reliable facts regarding
the current situation and possible clinical,
scientific, economical, and developmental
perspectives. Since we are not alone in the
decision making process, it is indeed our
responsibility to assist our partners to the
best of our abilities, in order to safeguard
all of the thrilling aspects that make our
profession attractive and promising, or to
be more explicitly, having access to the best
technologies for our patients, providing the
best training for our students, and making
the best out of our scientific ideas. We must
be convincing, and we must be heard.
The specialty section Heart Surgery in
Frontiers in Surgery is an ideal platform for
this. It will obviously incorporate all topics
in the field of cardiac surgery, with a spe-
cific emphasis on relevant R&D advances
and reliably performed clinical studies. But
we also aim to provide an interactive plat-
form for the exploration and discussion
around the limits of heart surgery, to go one
step beyond these frontiers and build our
future. Frontiers in Surgery with its section
Heart Surgery is therefore more than just
an additional journal by and for heart sur-
geons. It is a journal that integrates opin-
ions of all partners working alongside heart
surgeons to constantly improve quality in
heart surgery.
Let us face it; the good results of today’s
cardiac surgery cannot be attributed to a
mere handful of surgeons, even if very good
and highly publicized. It is rather, as it
has always been, due to the integrated and
coordinated forces of dedicated groups of
clinical partners, teams of surgeons, perfu-
sionists, anesthetists, and intensivists, very
well trained nursing staff, physiotherapists,
and rehabilitation specialists, as well as car-
diologists and general practitioners. Thus,
the greatest innovations in cardiac surgery
result from this shared vision and collab-
orative accomplishment. And this mind-
set must continue. In fact, we must con-
stantly reevaluate and make an effort to
understand the contributions and needs
of our partners. Three of these groups,
with whom our interactions represent both
ongoing and upcoming challenges, must
be considered very seriously, namely, (1)
the new generation of doctors, some of
whom will be our successors, (2) the scien-
tists who provide us with more and more
sophisticated biological and clinical tools
that must be integrated into our practice,
and (3) the industrial and the regulatory
partners, who take more and more inde-
pendence regarding the development, eval-
uation, and marketing of new technologies
and drugs.
DOES THE NEW GENERATION QUALIFY
TO TAKE OVER?
Whereas we were taught to work hard and
long hours in order to attain a solid train-
ing and reliable autonomy, the younger
generation clearly professes other priori-
ties and is definitely no longer willing to
forgo values like family and life balance.
Today, part-time clinical duties are not only
a demand of our women colleagues but
are also slowly becoming reality in surgical
units among both sexes and across all posi-
tions. In fact, more and more women suc-
cessfully complete cardiac surgery training
programs, leading to a more balanced ratio
of female:male surgeons. In many coun-
tries, working rules/laws have also become
more rigorous and force us to imagine
other models to guarantee quality patient
care. This may be criticized, but we can also
consider it as an opportunity to rethink our
model.
Whereas we basically lived together,
learned from each other, and were all always
informed about every aspect of our clinic,
perhaps we must start learning to commu-
nicate differently, delegate more, for exam-
ple, to dedicated internists who could run
our ward, and focus our energy more on
other specific aspects of our job in which
we excel. This change would, however,
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implicate a new, corporate way of thinking,
a new training mindset – in other words a
new culture. And it also would require new
structures with coordinators/managers in
order to reach another level of stability. Is it
really impossible? These are major changes,
yes. But other fields have undergone sim-
ilar restructuration, and no one questions
the fact that pilots are not allowed to fly
more than 30 h in 7 consecutive days, for
example.
WHAT CANWE LEARN FROM OUR
LABORATORY AND CLINICAL
SCIENTISTS?
The rapid development in biological and
material technologies makes it difficult
for clinicians, including heart surgeons,
to keep track of the true implications
or promises for daily activities. Follow-
ing the age of gene and cell therapy, it
seems that we are now entering a new
era of personalized medicine. However,
even though it is slowly becoming evi-
dent that each individual may respond
slightly differently to one specific therapy,
the bases for understanding these differ-
ences rely on highly specific knowledge
of the interaction between genomics, pro-
teomics, metabolomics, and environment,
and will thus probably remain obscure for
most of us. In other words, learning from
highly specialized new fields in medicine
may simply become an impossible task and
instead we might be forced just to trust it.
But we can still learn at a more tradi-
tional level of research and development.
And one would actually expect that learn-
ing nowadays be largely facilitated by the
relatively straightforward access to a very
large amount of information. For instance,
typing “cardiac surgery” in Pubmed pro-
vides 16,000 hits for the year 2013, whereas
it was 6,000 less only a decade ago, and
the evolution over these last years does not
show any evidence of reaching a plateau.
Do we really have so much more to pub-
lish these days than we did before? Or is
this representative of a win–win mental-
ity that is slowly gaining ground between
authors, who are still pushed to publish,
and publishers who use this opportunity
to expand their activity? Publishing was
originally aimed at informing peers about
results that could potentially help the com-
munity to achieve better outcomes. But too
many reports make it difficult to catch the
most relevant and the most appropriate
information. In addition to this phenom-
enon, an increasing number of frauds and
retractions have also been reported, con-
tributing to sow confusion in the med-
ical community. New ways of guaranty-
ing the quality of studies and publica-
tions are thus mandatory, and may include
the extension of monitoring and audit-
ing activities as well as certification of
research teams. Obligatory ethical approval
for every single study, including retrospec-
tive and quality oriented analyses,will likely
contribute to increasing the overall qual-
ity of reports and studies. Several groups
have also started assembling their results
in national or international registries, hav-
ing thus the opportunity for more precise
and detailed analyses. However, the value
of large amounts of compiled data is real-
ized only when these registries are repre-
sentative of the true situation and include
either all patients from a region or a coun-
try, such a national registry, or at least a
representative sample of this population.
This necessitates a data management struc-
ture with dedicated personnel, certified
material, and standard operating proce-
dures regarding data processing (data def-
initions, collection, checking, completing,
transfer, and archiving), data monitoring,
and independent data analysis (integrity
and transparency). In other words, it neces-
sitates a true professionalization of research
units, which represents a critical invest-
ment that is, effectively, not realistic for
every individual center.
SHALL WE RELY ON INDUSTRIAL
PARTNERS AND AUTHORITIES TO TAKE
CONTROL OF THE DEVELOPMENT OF
OUR FUTURE TECHNOLOGIES?
There was a time when pioneers used their
laboratories as true platforms for direct
translational development. Problems faced
in daily activities were mocked-up in vitro
or in vivo and solutions were rapidly trans-
ferred back to the clinic. This relatively
uncomplicated art of technology transfer,
even though unimaginable nowadays, truly
allowed the rapid development of cardiac
surgery and cardiology, and subsequently
the spectacular improvement, in less than
half of a century, of survival of patients
with cardiac diseases. Things have radically
changed and today ideas are rarely based
on needs originally identified by clinicians,
and clinicians rarely undertake the devel-
opment of their own ideas. It is a fact that
the pathway from an idea to a registered
and commercialized product has become,
over the years, a complex, lengthy, and
expensive process. But do we want our role
to be restricted; or do we want to take back
our roles as innovators and creative leaders,
and can we still do it?
In fact, one must first of all not forget
that clinicians still play a critical role in
product development. Some of us indeed
act as consultants for medical companies
or investigators in clinical trials. Never-
theless, the overall duration of new prod-
uct development until market authoriza-
tion has drastically increased in length and
complexity over the last two decades, espe-
cially for drug development, and a series of
specialized intermediary partners are now
needed to achieve this goal. In parallel, the
investment required for such development
has become colossal, and the risk that the
product will not be granted market autho-
rization remains high throughout devel-
opment. Consequently, companies tend to
limit their development pipeline to projects
with significant chances of success, whereas
other ideas may be abandoned early. As
clinicians, however, we remain those who
face the patients and we certainly do
not want to accept a reality dictated pri-
marily by economic interests. We there-
fore must be more active in the devel-
opment process, learn the basic aspects
related to translational research pathways
and integrate them into our training cur-
riculum and/or post-graduate education.
We need to take advantage of opportu-
nities, already existent in many countries,
to follow health management and med-
ical technology courses, which should, with
time, contribute to refocusing our way of
thinking onto our real needs and how to
realize them.
CONCLUSION
Cardiac surgery is only a few decades old,
but seems to have already reached maturity.
After a fantastic beginning, cardiac surgery
is currently undergoing a stable period, in
which results are good and patients seem
happy. But although no big revolution is
anticipated in the coming years, we can still
do better. For this, we must encourage our-
selves and our current and future collabo-
rators, our peer doctors, our scientists, our
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industrial partners, and our legal, ethical,
and regulatory partners to collaborate in
a new endeavor. Together, we can strive to
learn more, better, and faster in the cardio-
surgical field and to make this knowledge
available to our patients.
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